

Helsinki, 31 August 2018

Addressee: [REDACTED]

Decision number: TPE-D-2114440462-57-01/F  
Substance name: 2-(2-Vinyloxyethoxy)ethyl acrylate  
EC number: 451-690-9  
CAS number: 86273-46-3  
Registration number: [REDACTED]  
Submission number: [REDACTED]  
Submission date: 19 February 2016  
Registered tonnage band: 100-1000

### **DECISION ON A TESTING PROPOSAL**

Based on Article 40 of Regulation ((EC) No 1907/2006) (the REACH Regulation), ECHA examined your testing proposal(s) and decided as follows.

Your testing proposal is accepted and you are requested to carry out:

- 1. Viscosity (Annex IX, Section 7.17.; test method: OECD TG 114) using the registered substance.**
- 2. Sub-chronic toxicity study (90-day), oral route (Annex IX, Section 8.6.2.; test method: EU B.26./OECD TG 408) in rats using the registered substance.**
- 3. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: EU B.31./OECD TG 414) in a first species (rat or rabbit), oral route using the registered substance.**

You may adapt the testing requested above according to the specific rules outlined in Annexes VI to X and/or according to the general rules contained in Annex XI to the REACH Regulation. To ensure compliance with the respective information requirement, any such adaptation will need to have a scientific justification, referring and conforming to the appropriate rules in the respective annex, and an adequate and reliable documentation.

You have to submit the requested information in an updated registration dossier by **7 September 2020**. You also have to update the chemical safety report, where relevant. The timeline has been set to allow for sequential testing.

The reasons for this decision are set out in Appendix 1. The procedural history is described in Appendix 2 and advice and further observations are provided in Appendix 3.

## Appeal

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <http://echa.europa.eu/regulations/appeals>.

Authorised<sup>1</sup> by Ofelia Bercaru, Head of Unit, Evaluation E3

---

<sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

## **Appendix 1: Reasons**

The decision of ECHA is based on the examination of the testing proposals submitted by you and scientific information submitted by third parties.

### **1. Viscosity (Annex IX, Section 7.17.)**

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

"Viscosity" is a standard information requirement as laid down in Annex IX, Section 7.17 of the REACH Regulation. The information on this endpoint is not available for the registered substance subject to the present decision but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and you need to provide information for this endpoint.

You have submitted a testing proposal for a Viscosity of liquids (test method: OECD TG 114).

ECHA considers the proposed test appropriate and testing should be performed with the registered substance.

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed test using the registered substance: Viscosity of liquids (test method: OECD TG 114).

### **2. Sub-chronic toxicity study (90-day) (Annex IX, Section 8.6.2.)**

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

A sub-chronic toxicity study (90 day) is a standard information requirement as laid down in Annex IX, Section 8.6.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

You have submitted a testing proposal for a sub-chronic toxicity study (90 day) in rats by the oral route according to EU B.26./OECD TG 408.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Sub-chronic toxicity (90-day): oral. ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

You proposed testing by the oral route. Based on the information provided in the technical dossier and/or in the chemical safety report, ECHA agrees that the oral route - which is the preferred one as indicated in ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017) Chapter R.7a, Section R.7.5.4.3 - is the most appropriate route of administration. More specifically, even though the information indicates that human exposure to the registered substance by the inhalation route is likely, the exposure concentrations reported in the chemical safety report for the inhalation route is

low (maximum            mg/m<sup>3</sup>). Hence, the test shall be performed by the oral route using the test method EU B.26./OECD TG 408.

Therefore, ECHA considers that the proposed study performed by the oral route with the registered substance is appropriate to fulfil the information requirement of Annex IX, Section 8.6.2. of the REACH Regulation.

You proposed testing in rats. According to the test method EU B.26./OECD TG 408 the rat is the preferred species. ECHA considers this species as being appropriate and testing should be performed with the rat.

Therefore, pursuant to Article 40(3)(a)(b)(c) of the REACH Regulation, you are requested to carry out the proposed study with the registered substance subject to the present decision: Sub-chronic toxicity study (90-day) in rats, oral route (test method: EU B.26./OECD TG 408).

#### *Notes for your consideration*

ECHA notes that a revised version of OECD TG 408 was adopted this year by the OECD. This revised version contains enhancements of certain endocrine disrupting relevant parameters. You should test in accordance with the revised version of the guideline as published on the OECD website for adopted test guidelines ([https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects\\_20745788](https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788)).

### **3. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species**

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

A pre-natal developmental toxicity study for a first species is a standard information requirement as laid down in Annex IX, Section 8.7.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

You have submitted a testing proposal for a pre-natal developmental toxicity study in rats according to EU B.31./OECD TG 414 by the oral route.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Reproductive toxicity (pre-natal developmental toxicity). ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

ECHA considers that the proposed study performed with the registered substance is appropriate to fulfil the information requirement of Annex IX, Section 8.7.2. of the REACH Regulation.

You proposed testing with the rat as a first species. According to the test method EU B.31./OECD TG 414, the rat is the preferred rodent species and the rabbit the preferred

non-rodent species. On the basis of this default consideration, ECHA considers testing should be performed with the rat or rabbit as a first species.

ECHA agrees that the oral route is the most appropriate route of administration for substances except gases to focus on the detection of hazardous properties on reproduction as indicated in ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017) Chapter R.7a, Section R.7.6.2.3.2. Since the substance to be tested is a liquid, ECHA concludes that testing should be performed by the oral route.

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed study with the registered substance subject to the present decision: Pre-natal developmental toxicity study in a first species (rats or rabbits), oral route (test method: EU B.31./OECD TG 414).

*Notes for your consideration*

For the selection of the appropriate species you are advised to consult ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017), Chapter R.7a, Section R.7.6.2.3.2.

ECHA notes that a revised version of OECD TG 414 was adopted this year by the OECD. This revised version contains enhancements of certain endocrine disrupting relevant parameters. You should test in accordance with the revised version of the guideline as published on the OECD website for adopted test guidelines ([https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects\\_20745788](https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788)).

## **Appendix 2: Procedural history**

ECHA received your registration containing the testing proposals for examination in accordance with Article 40(1) on 2 November 2017.

ECHA held a third party consultation for the testing proposals from 20 December 2017 until 5 February 2018. ECHA did not receive information from third parties.

This decision does not take into account any updates after 18 May 2018, 30 calendar days after the end of the commenting period.

The decision making followed the procedure of Articles 50 and 51 of the REACH Regulation, as described below:

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments by the end of the commenting period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA took the decision according to Article 51(3) of the REACH Regulation.

**Appendix 3: Further information, observations and technical guidance**

1. This decision does not imply that the information provided in your registration dossier is in compliance with the REACH requirements. The decision does not prevent ECHA from initiating a compliance check on the registration at a later stage.
2. Failure to comply with the requests in this decision, or to otherwise fulfil the information requirements with a valid and documented adaptation, will result in a notification to the enforcement authorities of the Member States.
3. In carrying out the tests required by the present decision, it is important to ensure that the particular sample of substance tested is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured or imported. If the registration of the substance covers different grades, the sample used for the new tests must be suitable to assess these.

Furthermore, there must be adequate information on substance identity for the sample tested and the grades registered to enable the relevance of the tests to be assessed.